BioCentury | Sep 28, 2019
Company News

Management tracks: Bourla to succeed Read as Pfizer chair; plus Phathom, OnKure, Forma, Beam, Noven, Cerebral, Alpha Tau and InsightRX

...was VP, operations at Catalent Inc. (NYSE:CTLT). The Noven Pharmaceuticals Inc. specialty drug subsidiary of Hisamitsu Pharmaceutical Co. Inc....
...who is resigning. Higo has been Noven’s chairman since 2017 board and has been with Hisamitsu...
...was director of product marketing at Roam Analytics Inc. Jonathan Block, Associate Editor Pfizer Inc. Forma Therapeutics Inc. Beam Therapeutics Hisamitsu Pharmaceutical Co. Inc. Cerebral...
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

...research. She was interim head of research at the Muscular Dystrophy Association. BioCentury Staff Passage Bio Inc. Novartis AG Hisamitsu Pharmaceutical Co. Inc. Illumina...
BioCentury | Jul 11, 2019
Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

...Partners, where he continues as partner emeritus. The Noven Pharmaceuticals Inc. specialty drug subsidiary of Hisamitsu...
...and Hongjiang Li, Staff Writers Alnylam Pharmaceuticals Inc. Atreca Inc. AZTherapies Inc. Eli Lilly and Co. Gilead Sciences Inc. GlaxoSmithKline plc Healx Ltd. Hisamitsu Pharmaceutical Co. Inc. Tizona...
BioCentury | Feb 9, 2018
Clinical News

Hisamitsu's HP-3070 meets in Phase III for schizophrenia

...to week six vs. placebo. Additional data are slated for publication at future scientific meetings. Hisamitsu...
...transdermal patch formulation of the antipsychotic asenapine maleate using Hisamitsu’s Transdermal Drug Delivery System (TDDS). Hisamitsu Pharmaceutical Co. Inc....
...Business: Neurology Molecular target: NA Description: Transdermal patch formulation of the antipsychotic asenapine maleate using Hisamitsu’s...
BioCentury | Sep 1, 2017
Clinical News

Hisamitsu begins Ph III trial fo HP-3150 for cancer pain

...cancer pain trial, but did not provide details. HP-3150 is a transdermal patch containing NSAIDs. Hisamitsu Pharmaceutical Co. Inc....
...Treat cancer pain Endpoint: Efficacy; safety Status: Phase III started Milestone: Submit regulatory application (2020) Alicia Parker HP-3150 Hisamitsu Pharmaceutical Co. Inc....
BioCentury | Dec 21, 2016
Clinical News

HP-3060 regulatory update

...drug delivery system. Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530), Tosu, Japan Product: Emedastine fumarate ( HP-3060 ) Business: Inflammation Julian Zhu HP-3060 Hisamitsu Pharmaceutical Co. Inc. Histamine...
BioCentury | Sep 12, 2016
Clinical News

HP-3150: Phase II/III data

...trial of HP-3150 in patients with cancer pain. The company declined to provide further details. Hisamitsu Pharmaceutical Co. Inc....
BioCentury | Sep 12, 2016
Clinical News

Asenapine maleate transdermal patch: Phase III started

...trial to evaluate 2 dose levels of asenapine maleate transdermal patches in about 612 patients. Hisamitsu Pharmaceutical Co. Inc....
...Business: Neurology Molecular target: NA Description: Transdermal tape formulation of the antipsychotic asenapine developed using Hisamitsu’s...
BioCentury | Sep 28, 2015
Clinical News

HP-3150: Phase II started

...a placebo-controlled, Japanese Phase II trial to evaluate HP-3150 in patients with lower back pain. Hisamitsu Pharmaceutical Co. Inc....
BioCentury | Jul 20, 2015
Clinical News

HP-3150: Phase II/III started

...began a placebo-controlled, Japanese Phase II/III trial to evaluate HP-3150 in patients with cancer pain. Hisamitsu Pharmaceutical Co. Inc....
Items per page:
1 - 10 of 90
BioCentury | Sep 28, 2019
Company News

Management tracks: Bourla to succeed Read as Pfizer chair; plus Phathom, OnKure, Forma, Beam, Noven, Cerebral, Alpha Tau and InsightRX

...was VP, operations at Catalent Inc. (NYSE:CTLT). The Noven Pharmaceuticals Inc. specialty drug subsidiary of Hisamitsu Pharmaceutical Co. Inc....
...who is resigning. Higo has been Noven’s chairman since 2017 board and has been with Hisamitsu...
...was director of product marketing at Roam Analytics Inc. Jonathan Block, Associate Editor Pfizer Inc. Forma Therapeutics Inc. Beam Therapeutics Hisamitsu Pharmaceutical Co. Inc. Cerebral...
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

...research. She was interim head of research at the Muscular Dystrophy Association. BioCentury Staff Passage Bio Inc. Novartis AG Hisamitsu Pharmaceutical Co. Inc. Illumina...
BioCentury | Jul 11, 2019
Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

...Partners, where he continues as partner emeritus. The Noven Pharmaceuticals Inc. specialty drug subsidiary of Hisamitsu...
...and Hongjiang Li, Staff Writers Alnylam Pharmaceuticals Inc. Atreca Inc. AZTherapies Inc. Eli Lilly and Co. Gilead Sciences Inc. GlaxoSmithKline plc Healx Ltd. Hisamitsu Pharmaceutical Co. Inc. Tizona...
BioCentury | Feb 9, 2018
Clinical News

Hisamitsu's HP-3070 meets in Phase III for schizophrenia

...to week six vs. placebo. Additional data are slated for publication at future scientific meetings. Hisamitsu...
...transdermal patch formulation of the antipsychotic asenapine maleate using Hisamitsu’s Transdermal Drug Delivery System (TDDS). Hisamitsu Pharmaceutical Co. Inc....
...Business: Neurology Molecular target: NA Description: Transdermal patch formulation of the antipsychotic asenapine maleate using Hisamitsu’s...
BioCentury | Sep 1, 2017
Clinical News

Hisamitsu begins Ph III trial fo HP-3150 for cancer pain

...cancer pain trial, but did not provide details. HP-3150 is a transdermal patch containing NSAIDs. Hisamitsu Pharmaceutical Co. Inc....
...Treat cancer pain Endpoint: Efficacy; safety Status: Phase III started Milestone: Submit regulatory application (2020) Alicia Parker HP-3150 Hisamitsu Pharmaceutical Co. Inc....
BioCentury | Dec 21, 2016
Clinical News

HP-3060 regulatory update

...drug delivery system. Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530), Tosu, Japan Product: Emedastine fumarate ( HP-3060 ) Business: Inflammation Julian Zhu HP-3060 Hisamitsu Pharmaceutical Co. Inc. Histamine...
BioCentury | Sep 12, 2016
Clinical News

HP-3150: Phase II/III data

...trial of HP-3150 in patients with cancer pain. The company declined to provide further details. Hisamitsu Pharmaceutical Co. Inc....
BioCentury | Sep 12, 2016
Clinical News

Asenapine maleate transdermal patch: Phase III started

...trial to evaluate 2 dose levels of asenapine maleate transdermal patches in about 612 patients. Hisamitsu Pharmaceutical Co. Inc....
...Business: Neurology Molecular target: NA Description: Transdermal tape formulation of the antipsychotic asenapine developed using Hisamitsu’s...
BioCentury | Sep 28, 2015
Clinical News

HP-3150: Phase II started

...a placebo-controlled, Japanese Phase II trial to evaluate HP-3150 in patients with lower back pain. Hisamitsu Pharmaceutical Co. Inc....
BioCentury | Jul 20, 2015
Clinical News

HP-3150: Phase II/III started

...began a placebo-controlled, Japanese Phase II/III trial to evaluate HP-3150 in patients with cancer pain. Hisamitsu Pharmaceutical Co. Inc....
Items per page:
1 - 10 of 90